Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 8:21 pm Purchase | 13G | Lantheus Holdings Inc. LNTH | Farallon Capital Partners L.P. | 5,064,227 7.300% | 5,064,227 (New Position) | View |
| 2024-11-08 5:15 pm Purchase | 13G | Longboard Pharmaceuticals Inc. LBPH | Farallon Capital Partners L.P. | 3,456,063 9.990% | 1,250,073 (+56.67%) | View |
| 2024-11-08 2:57 pm Sale | 13G | Aramark ARMK | Farallon Capital Partners L.P. | 11,636,937 4.400% | -5,262,317 (-31.14%) | View |
| 2024-11-08 2:40 pm Purchase | 13G | AGIOS PHARMACEUTICALS INC. AGIO | Farallon Capital Partners L.P. | 5,660,866 9.900% | 1,493,264 (+35.83%) | View |
| 2024-11-08 11:54 am Purchase | 13G | Elevation Oncology Inc. ELEV | Farallon Capital Partners L.P. | 3,527,482 6.000% | 427,482 (+13.79%) | View |
| 2024-11-07 09:56 am Purchase | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 8,208,123 9.900% | 4,102,370 (+99.92%) | View |
| 2024-11-06 6:32 pm Purchase | 13G | Savara Inc SVRA | Farallon Capital Partners L.P. | 17,762,533 9.990% | 3,435,622 (+23.98%) | View |
| 2024-11-06 5:06 pm Sale | 13G | SWIFTMERGE ACQ.CORP UNIT 1 CL IVCPU | Farallon Capital Partners L.P. | 471,366 9.900% | -53,634 (-10.22%) | View |
| 2024-10-16 4:35 pm Purchase | 13D | Squarespace Inc. SQSP | Farallon Capital Partners L.P. | 5,600,000 6.100% | 5,600,000 (New Position) | View |
| 2024-05-17 4:58 pm Purchase | 13G | NANOSTRING TECHNOLOGIES INC CO NSTGQ | Farallon Capital Partners L.P. | 4,391,941 9.100% | 4,391,941 (New Position) | View |
| 2024-05-08 4:11 pm Purchase | 13D | EXELIXIS INC. EXEL | Farallon Capital Partners L.P. | 26,769,500 9.200% | 909,500 (+3.52%) | View |
| 2024-02-14 09:33 am Purchase | 13G | FORTE BIOSCIENCES INC FBRX | Farallon Capital Partners L.P. | 3,793,497 9.900% | 5,861 (+0.15%) | View |
| 2024-02-12 5:11 pm Sale | 13G | Revolution Medicines Inc. RVMD | Farallon Capital Partners L.P. | 6,750,204 4.100% | -12,276 (-0.18%) | View |
| 2024-02-12 3:38 pm Sale | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 4,105,753 5.000% | -7,716 (-0.19%) | View |
| 2024-02-08 11:39 am Purchase | 13G | AGIOS PHARMACEUTICALS INC. AGIO | Farallon Capital Partners L.P. | 4,167,602 7.500% | 206,000 (+5.20%) | View |
| 2024-02-06 10:16 am Purchase | 13G | Aramark ARMK | Farallon Capital Partners L.P. | 16,899,254 6.400% | 1,518,185 (+9.87%) | View |
| 2024-02-05 5:28 pm Unchanged | 13D | Cazoo Group Ltd CZOOF | Farallon Capital Partners L.P. | 714,240 14.600% | 0 (Unchanged) | View |
| 2024-02-05 11:22 am Sale | 13G | SWIFTMERGE ACQ.CORP UNIT 1 CL IVCPU | Farallon Capital Partners L.P. | 525,000 9.000% | -1,680,000 (-76.19%) | View |
| 2024-02-02 09:19 am Purchase | 13G | Protagonist Therapeutics Inc PTGX | Farallon Capital Partners L.P. | 5,765,109 9.990% | 710,007 (+14.05%) | View |
| 2024-02-01 3:50 pm Purchase | 13G | Savara Inc SVRA | Farallon Capital Partners L.P. | 14,326,911 9.990% | 2,794,289 (+24.23%) | View |